PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays

Immune checkpoint blockade (ICB) drugs are a novel, effective treatment for advanced urothelial carcinoma. Worldwide, several different ICB drugs are approved, each developed and clinically validated with a specific PD-L1 compound diagnostic assay. As a result, PD-L1 testing workflows in routine pra...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Harriet, O’Sullivan, Brendan, Hughes, Frances, Charles, Kathryn, Robertson, Lee, Taniere, Philippe, Diaz-Cano, Salvador
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036367/
https://www.ncbi.nlm.nih.gov/pubmed/35478498
http://dx.doi.org/10.3389/pore.2022.1610260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036367/
https://www.ncbi.nlm.nih.gov/pubmed/35478498
http://dx.doi.org/10.3389/pore.2022.1610260

Ejemplares similares